AU2021368635A1 - Anti-vertigo compound and pharmaceutical compositions thereof - Google Patents

Anti-vertigo compound and pharmaceutical compositions thereof Download PDF

Info

Publication number
AU2021368635A1
AU2021368635A1 AU2021368635A AU2021368635A AU2021368635A1 AU 2021368635 A1 AU2021368635 A1 AU 2021368635A1 AU 2021368635 A AU2021368635 A AU 2021368635A AU 2021368635 A AU2021368635 A AU 2021368635A AU 2021368635 A1 AU2021368635 A1 AU 2021368635A1
Authority
AU
Australia
Prior art keywords
levocloperastine
vertigo
pharmaceutically acceptable
composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021368635A
Other languages
English (en)
Other versions
AU2021368635A9 (en
Inventor
Nirav Vyas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amneal Pharmaceuticals LLC
Original Assignee
Kashiv Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kashiv Biosciences LLC filed Critical Kashiv Biosciences LLC
Publication of AU2021368635A1 publication Critical patent/AU2021368635A1/en
Assigned to KASHIV BIOSCIENCES, LLC reassignment KASHIV BIOSCIENCES, LLC Request for Assignment Assignors: AMERISE PHARMACEUTICALS PVT LTD.
Publication of AU2021368635A9 publication Critical patent/AU2021368635A9/en
Assigned to Amneal Pharmaceuticals, LLC reassignment Amneal Pharmaceuticals, LLC Request for Assignment Assignors: KASHIV BIOSCIENCES, LLC
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021368635A 2020-10-28 2021-09-10 Anti-vertigo compound and pharmaceutical compositions thereof Pending AU2021368635A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202021047025 2020-10-28
IN202021047025 2020-10-28
PCT/IN2021/050886 WO2022091118A1 (en) 2020-10-28 2021-09-10 Anti-vertigo compound and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
AU2021368635A1 true AU2021368635A1 (en) 2023-06-08
AU2021368635A9 AU2021368635A9 (en) 2024-02-08

Family

ID=81382136

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021368635A Pending AU2021368635A1 (en) 2020-10-28 2021-09-10 Anti-vertigo compound and pharmaceutical compositions thereof

Country Status (7)

Country Link
US (1) US20230390271A1 (https=)
EP (1) EP4236923A4 (https=)
JP (1) JP7837967B2 (https=)
CN (1) CN116963737A (https=)
AU (1) AU2021368635A1 (https=)
CA (1) CA3200533A1 (https=)
WO (1) WO2022091118A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4299059A1 (en) 2022-07-01 2024-01-03 Labelic Analysis, S.L. Composition for the treatment of tinnitus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228561B (it) * 1989-03-03 1991-06-21 Magis Farmaceutici Isomero otticamente attivo della cloperastina avente attivita' antitussiva, processo per la sua preparazione e composizioni farmaceutiche che lo contengono.
EP0894794A1 (en) * 1997-07-31 1999-02-03 AESCULAPIUS FARMACEUTICI S.r.l. Optical isomers of cloperastine
JP2004269513A (ja) 2003-02-19 2004-09-30 Rohto Pharmaceut Co Ltd 固形製剤
US20090176792A1 (en) * 2008-01-07 2009-07-09 Auspex Pharmaceuticals, Inc. Substituted dibenzhydrylpiperazines
WO2019004953A1 (en) * 2017-06-29 2019-01-03 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi LEVOCLOPERASTIN FENDIZOATE SUSPENSION HAVING IMPROVED DISSOLUTION AND SUSPENSION CAPACITY

Also Published As

Publication number Publication date
EP4236923A1 (en) 2023-09-06
EP4236923A4 (en) 2024-09-25
WO2022091118A1 (en) 2022-05-05
JP7837967B2 (ja) 2026-03-31
CA3200533A1 (en) 2022-05-05
US20230390271A1 (en) 2023-12-07
CN116963737A (zh) 2023-10-27
AU2021368635A9 (en) 2024-02-08
JP2024506229A (ja) 2024-02-13

Similar Documents

Publication Publication Date Title
US20220265624A1 (en) Sustained release aminopyridine composition
ES2935800T3 (es) Forma de dosificación oral de ketamina
ES2525005T3 (es) Formulación de liberación prolongada que contiene una cera
ES2405404T3 (es) Composiciones farmacéuticas de liberación sostenida que comprenden aplindore y sus derivados
KR102241643B1 (ko) 비정질 톨밥탄을 함유하는 경구 투여 현탁제
US12016951B2 (en) Edaravone pharmaceutical composition
US9744170B2 (en) Solid antiviral dosage forms
SG176934A1 (en) Pharmaceutical composition having improved solubility
JP6093762B2 (ja) 徐放性製剤
US7943585B2 (en) Extended release antibiotic composition
US20110251239A1 (en) Combination therapy for the treatment of dementia
EP4236923A1 (en) Anti-vertigo compound and pharmaceutical compositions thereof
WO2019016673A2 (en) STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
US20100272794A1 (en) Pharmaceutical composition of memantine
CN111787922A (zh) 用于治疗肝细胞癌的组合疗法
US20230233470A1 (en) Formulations
US20220193043A1 (en) Pharmaceutical Combination Formulations Comprising Tizanidine, Resveratrol and Piperine
US20240269083A1 (en) Prolonged-release pharmaceutical composition for oral administration of sultiame
WO2005016315A1 (en) Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
KR20240173178A (ko) 안정성 및 용출률이 개선된 크리스데살라진 함유 약학 조성물
CN117355296A (zh) 用于口服施用舒噻美的延长释放药物组合物
JP2002179573A (ja) 緑内障治療剤及び高眼圧症治療剤
HK1134036A (en) Formulations of flibanserin and method for manufacturing the same

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: KASHIV BIOSCIENCES, LLC

Free format text: FORMER APPLICANT(S): AMERISE PHARMACEUTICALS PVT LTD.

SREP Specification republished
PC1 Assignment before grant (sect. 113)

Owner name: AMNEAL PHARMACEUTICALS, LLC

Free format text: FORMER APPLICANT(S): KASHIV BIOSCIENCES, LLC